Key takeaways
Gemtesa belongs to a drug class called beta-3 adrenergic agonists.
Gemtesa alternatives include Myrbetriq and antimuscarinic medications.
The best alternative depends on side effects, health conditions, and cost.
Gemtesa is a brand-name medication used to treat overactive bladder (OAB) symptoms, including urinary urgency, frequent urination, and incontinence. Vibegron, the generic name for Gemtesa, belongs to a class of medications called beta agonists. It relaxes the bladder muscle, allowing it to hold more urine. Gemtesa may not be suitable for everyone because of side effects, health conditions, or cost. Gemtesa alternatives include another beta-3 agonist or a muscarinic antagonist.
Save up to 80% on Gemtesa with SingleCare
Different pharmacies offer different prices for the same medication. SingleCare helps find the best price for you.
RELATED: What is Gemtesa?
What can I take instead of Gemtesa?
Alternatives to Gemtesa include Myrbetriq (mirabegron), antimuscarinic medications, and, for some people, Botox injections. The standard Gemtesa dosage is 75 mg once daily, but alternative treatments have different dosages, risks, and benefits. A healthcare provider can recommend an option based on your symptoms, health history, and previous treatments.
Compare Gemtesa alternatives |
|||
|---|---|---|---|
| Drug name | Price without insurance | SingleCare price | Savings options |
| Gemtesa (vibegron) | $688 for 30, 75 mg tablets | $442 for 30, 75 mg tablets of brand-name Gemtesa at Kroger | See latest prices |
| Myrbetriq (mirabegron extended-release)) | $624 for 30, 50 mg tablets | $189 for 30, 50 mg tablets of generic Myrbetriq at CVS Pharmacy | See latest prices |
| Oxybutynin extended-release (ER) | $104 for 30, 10 mg tablets | $10 for 30, 10 mg tablets of generic oxybutynin ER at Kroger | See latest prices |
| VESIcare (solifenacin succinate) | $479 per 30, 10 mg tablets | $14 per 30, 10 mg tablets of generic VESIcare at Food Lion | See latest prices |
| Tolteridone | $213 per 60, 2 mg tablets | $24 per 60, 2 mg tablets of generic tolterodine at Kroger | See latest prices |
| Darifenacin ER | $332 per 30, 15 mg tablets | $29 per 30, 15 mg tablets of generic darifenacin ER at CVS Pharmacy | See latest prices |
Top 5 Gemtesa alternatives
The following are some of the most common alternatives to Gemtesa.
1. Myrbetriq (mirabegron)
Myrbetriq (mirabegron) is the only other beta-3 adrenergic agonist approved for OAB, making it one of the most similar alternatives to Gemtesa. Both medications relax the bladder muscle to allow more urine storage and reduce urgency and frequency. According to the Myrbetriq prescribing information, Myrbetriq can increase blood pressure and is not recommended for people with severe uncontrolled hypertension. Common side effects include urinary tract infections, headaches, and cold-like symptoms. Less common side effects may also affect its suitability.
2. Oxybutynin
Oxybutynin is an antimuscarinic medication that works differently from Gemtesa by reducing involuntary bladder contractions. Oral oxybutynin is available in immediate-release and extended-release tablets. Common oxybutynin side effects include dry mouth, constipation, drowsiness, and dizziness. Oxybutynin has also been associated with cognitive effects, including confusion and memory problems, which are a particular concern for older adults.
3. VESIcare
VESIcare (solifenacin) is a once-daily tablet approved to treat overactive bladder in adults. Unlike Gemtesa, it is a muscarinic antagonist that reduces involuntary bladder contractions. According to the VESIcare prescribing information, common side effects include dry mouth, constipation, urinary tract infections, and blurred vision.
4. Detrol (tolterodine)
Tolterodine is the generic version of Detrol. It is an antimuscarinic medication that reduces involuntary bladder contractions and helps relieve urinary urgency, frequency, and incontinence. Tolterodine is available in immediate-release tablets and extended-release capsules. According to the prescribing information, common side effects of the extended-release form include dry mouth, headache, constipation, and abdominal pain. As a generic medication, tolterodine may be a more affordable alternative to Gemtesa.
5. Darifenacin
Darifenacin ER is the generic version of Enablex. It is a once-daily antimuscarinic medication used to treat urinary urgency, frequency, and incontinence. Because Gemtesa has no generic version and can be expensive without insurance, darifenacin may be a lower-cost option. According to the darifenacin prescribing information, common side effects include dry mouth, constipation, headache, indigestion, and nausea. Patients who remain on Gemtesa can also explore available Gemtesa savings options.
Natural alternatives to Gemtesa
Lifestyle and behavioral changes may help manage OAB symptoms. The National Association for Continence suggests identifying bladder irritants, such as caffeine, citrus, and spicy foods. Other options include bladder training, pelvic floor muscle exercises, and adjusting fluid intake under the guidance of a healthcare provider. These approaches may be used alone or alongside medication, depending on the severity of the symptoms.
How to switch to a Gemtesa alternative
Talk to your healthcare provider before stopping Gemtesa or starting another OAB medication. They may recommend another beta-3 adrenergic agonist, such as Myrbetriq, or an antimuscarinic medication, such as VESIcare. The best option depends on your symptoms, medical history, current medications, and risk of side effects. Gemtesa generally does not need to be stopped gradually as withdrawal symptoms are not expected. Follow your provider’s instructions on when to stop Gemtesa and begin the new treatment.
The SingleCare prices in this article are the most accurate at the time of publishing in ZIP code 23666 as of Aug. 11, 2026. Prices vary by pharmacy. Visit our coupon page for updated drug prices at pharmacies near you.
- Myrbetriq mirabegron tablet prescribing information, DailyMed (NIH National Library of Medicine) (2024)
- Oxybutynin-associated cognitive impairment: evidence and implications for overactive bladder treatment, UroToday (2024)
- VESIcare solifenacin succinate tablet prescribing information, DailyMed (NIH National Library of Medicine) (2022)
- Tolterodine tartrate extended-release capsule prescribing information, DailyMed (NIH National Library of Medicine) (2025)
- Darifenacin extended-release tablet prescribing information, DailyMed (NIH National Library of Medicine) (2025)
- What is overactive bladder (OAB)?, National Association for Continence (2026)
- Medically accurate: SingleCare’s Medical Review Board analyzes all of our content to confirm it’s in line with current medical advice.
- Evidence-based: Our content is sourced from reputable U.S.-based healthcare professionals and peer-reviewed research.
- Trustworthy: All of SingleCare’s content goes through a multi-phase review process by our writers, editors, and Medical Board in order to provide clear and credible information.